Beyond galactose-deficient IgA1: reconsidering IgA2 as a pathogenic driver in IgA nephropathy
Authors:
- 20 May 2026
- journal article
- editorial
- Published by Elsevier in Kidney International
- Vol. 109 (6) , 1091-1094
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (445703531)
This publication has 17 references indexed in Scilit:
- Absence of glomerular IgA1 deposition despite overexpression of galactose-deficient IgA1 in the B cell c1galt1 knockout mouseKidney International, 2026
- Evidence from multicenter clinical studies and humanized mouse models indicates that glomerular mesangial IgA2 deposition contributes to the pathogenesis of IgA nephropathyKidney International, 2026
- Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathyKidney International, 2025
- Secretory IgA: controlling the gut microbiotaNature Reviews Gastroenterology & Hepatology, 2021
- IgA subclasses have different effector functions associated with distinct glycosylation profilesNature Communications, 2020
- Activation of the lectin complement pathway in Henoch-Schönlein purpura nephritisAmerican Journal of Kidney Diseases, 2005
- Incidence of latent mesangial IgA deposition in renal allograft donors in JapanKidney International, 2003
- Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgGKidney International, 1997
- Studies of the molecular basis of IgA production, subclass regulation and class-switch recombination in IgA nephropathy patientsClinical and Experimental Immunology, 1996
- The structure and function of human IgABiochemical Journal, 1990